YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The 2026 European Association for the Study of Diabetes ("EASD") annual meeting in Milan has become the stage for a fierce data duel between Eli Lilly LLY and Novo Nordisk NVO. Both pharma giants unveiled new clinical evidence to bolster t…
In a landmark move beginning July 1, 2026, Medicare, under its "GLP-1 Bridge" demonstration program, is set to provide eligible U.S. seniors with access to popular weight-loss medications like Wegovy, Zepbound, and Foundayo for a copay of…
[Injectable semaglutide pens for glucose control with a blue measuring tape on a clean background for weight loss and medical themes.] Eduardo Monroy Husillos/iStock via Getty Images Millions of Americans are set to gain access to certain…
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since…
The weight loss drug market has evolved into one of the most explosive, flourishing segments of the global healthcare industry, driven by an unprecedented surge in demand for glucagon-like peptide-1 (GLP-1) receptor agonists. At the center…
The FDA recently approved higher-dose version of Novo Nordisk’s NVO obesity drug Wegovy, further expanding the drug giant’s footprint in the rapidly growing and fiercely competitive weight-loss market. Announced on March 19, 2026, the appr…
Shares of Danish drugmaker Novo Nordisk NVO suffered a sharp slump of 15% on the bourses on Tuesday, after the company issued a conservative sales outlook that implied a 5-13% decline in 2026 from last year. This news also triggered a broa…
The recent U.S. Food and Drug Administration (FDA) approval of Novo Nordisk’s NVO oral obesity pill, Wegovy, marks a significant turning point in the fiercely competitive weight-loss drug market. This pill, the first GLP-1 tablet specifica…
Eli Lilly LLY briefly crossed the $1 trillion market cap on Nov. 21, 2025 — becoming the first-ever health-care company to join the elite group mainly dominated by tech giants, as mentioned on CNBC. Shares touched around $1,059 on the day.…
The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question. On Sept. 9, the agency sent warning letters to Eli Lilly And Co (N…
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease. The stock gained more than 1% in…
Shares of Danish pharmaceutical giant Novo Nordisk A/S (NVO) tumbled 22% Tuesday after the company slashed its 2025 outlook and announced a CEO change, sending shockwaves through a range of ETFs tied to weight-loss drugs. Novo, best known…
Photo by Clay Banks via Unsplash GLP-1 investors haven’t gained as much as expected from others’ losses. Since the FDA approved Wegovy, also known as semaglutide, as an injectactable treatment to help people manage their weight, several ex…